Entering text into the input field will update the search result below

TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q1 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

TherapeuticsMD, Inc. (NASDAQ:TXMD) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET

Company Participants

Nichol Ochsner - Vice President of Investor Relations

Rob Finizio - Chief Executive Officer

James D'Arecca - Chief Financial Officer

Dawn Halkuff - Chief Commercial Officer

Mitchell Krassan - Chief Strategy & Performance Officer

Conference Call Participants

Dana Flanders - Guggenheim Partners

Douglas Tsao - H.C. Wainwright


Good morning, ladies and gentlemen. Thank you for joining us for TherapeuticsMD First Quarter 2021 Financial Results Conference Call. Following prepared remarks from the company, we will open the call for questions.

I would now like to turn the call over to TherapeuticsMD's Vice President of Investor Relations, Nichol Ochsner. Nichol?

Nichol Ochsner

Good morning, everyone. Thank you for joining today to discuss our first quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing our first quarter financial results. The press release is available on the Company's website, therapeuticsmd.com in the Investors and Media section. On today's call from TherapeuticsMD are Chief Executive Officer, Rob Finizio; Chief Financial Officer, James D'Arecca; Chief Commercial Officer, Dawn Halkuff; and Chief Strategy & Performance Officer, Mitchell Krassan. I would like to remind everyone that certain statements made during this conference call may be forward-looking statements.

Such forward-looking statements are based upon current expectations, and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors and risks some of which are identified in our press release and our annual, quarterly and other reports filed with the SEC. These forward-looking statements are based on information available to TherapeuticsMD today, and the company assumes no obligation to update statements as circumstances change. An audio recording and webcast replay for today's conference call will also

Recommended For You

Comments (3)

I have commented over the past year and a half that this company wont exist much longer. TXMD exists only to keep paying fat salaries to management. When the stock was higher, they cashed out. Now they are just riding this into the sunset until the company is sold off for pennies.

I bet their trying to figure out how to do the next secondary at .50 cents as a last gasp to keep the racket going a few more months.

Must have blown through a billion dollars for virtually no sales.
Flim Flam at it again
Pathetic. $50M of quarterly spending for $20M in sales. Hundreds of millions spent for two pathetic products that generate less than $20M in annual sales. Excuse after excuse every single quarter. When is profitability projected now? How many more dilutive equity raises in the remainder of 2021?
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About TXMD

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on TXMD

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.